Tobramycin Eye Drops Dosing Regimen
For mild to moderate bacterial conjunctivitis or external eye infections, instill 1-2 drops into the affected eye(s) every 4 hours; for severe infections including bacterial keratitis, instill 2 drops hourly until improvement, then taper frequency before discontinuation. 1
Dosing by Severity
Mild to Moderate Disease
- 1-2 drops every 4 hours into affected eye(s)
- Typical duration: 5-7 days
- This applies to most cases of bacterial conjunctivitis and minor external eye infections 1
Severe Infections (Bacterial Keratitis)
- Loading dose: 2 drops every 5-15 minutes initially
- Maintenance: 2 drops every hour around the clock
- Continue hourly dosing until clinical improvement is evident
- Taper gradually as infection resolves—do not drop below therapeutic levels as this may promote antibiotic resistance 2
- Consider fortified tobramycin (14 mg/mL) for large infiltrates >2mm or presence of hypopyon 2
Clinical Monitoring for Tapering
Reduce frequency when you observe:
- Decreased pain and discharge
- Reduced lid edema and conjunctival injection
- Sharper demarcation of stromal infiltrate borders
- Decreased stromal density without progressive thinning
- Initial re-epithelialization 2
Important Caveats
Avoid subtherapeutic dosing during taper—prolonged use of inadequate antibiotic concentrations increases resistance risk. However, prolonged use also causes medication toxicity and can worsen inflammation or cause corneal melting 2.
Ointment formulations have poor corneal penetration and should only be used at bedtime for mild cases or as adjunctive therapy, never as primary treatment for keratitis 2.
Resistance considerations: Tobramycin resistance is increasing, particularly in gram-negative organisms and MRSA isolates. If no improvement occurs within 48 hours, consider reculture and switching to fluoroquinolones or fortified antibiotics 3, 2.
For contact lens-related infections, always prescribe prophylactic antibiotics for corneal abrasions and never patch the eye, as this increases bacterial keratitis risk 2.